Understanding Your Rights as an Agenus Inc. Investor
Are you an investor in Agenus Inc. and wondering about your rights? Recently, investors have been alerted regarding an ongoing securities fraud class action lawsuit against Agenus Inc. (NASDAQ: AGEN). This legal action serves to protect the interests of those who may have fallen victim to potentially misleading information from the company.
Who Should Pay Attention?
Investors who bought shares of Agenus Inc. between January 23, 2023, and July 17, 2024, are directly impacted. If you held shares during this time frame and have concerns about your investment’s performance, it’s crucial to review your options.
Key Questions for Investors
When navigating through this situation, consider these important questions:
- Did you own shares of Agenus Inc. during the specified class period?
- Have you experienced financial losses related to your investments in Agenus?
- Would you like to talk about the implications for your investment?
This is the perfect time to have these discussions, as being informed is key to making the right decisions concerning your investments.
About the Class Action Lawsuit
The lawsuit, filed in the United States District Court for the District of Massachusetts, alleges that Agenus misrepresented critical information about its investigational therapy for metastatic colorectal cancer. This seemingly misleading information could have influenced your investment decisions, highlighting the importance of staying informed.
What’s Next for Interested Investors?
If you purchased Agenus securities and want to explore your options, it’s essential to act swiftly. You have the right to serve as a lead plaintiff, representing others in your situation. However, you must submit your papers by November 5, 2024, to be considered.
Legal Support and Contingency Representation
Bernstein Liebhard LLP, recognized for their dedication to investor rights, is representing individuals harmed by deceptive practices in the marketplace. Importantly, all legal representation is provided on a contingency fee basis, which means no fees unless there are successful outcomes.
This established law firm has an impressive track record, having recovered over $3.5 billion for clients since its inception. They actively work not only with individual investors but also with large pension funds to safeguard and pursue monetary recovery on behalf of their clients.
Contact Information for Further Inquiry
If you have questions or need assistance regarding the class action lawsuit, consider reaching out for guidance. You can contact:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
Phone: (212) 951-2030
Email: pallocco@bernlieb.com
Frequently Asked Questions
What should I do if I invested in Agenus Inc.?
If you bought shares between the specified dates, it’s advisable to gather your documentation and evaluate your legal options.
Who can participate in the class action?
Investors who purchased Agenus securities during the listed timeframe can take part in the class action lawsuit.
What are the costs involved in pursuing this lawsuit?
There are no upfront costs, as representation is contingent upon successful recovery.
How long do I have to join the lawsuit?
The deadline to file your papers is November 5, 2024.
What happens if I don’t file?
If you choose not to take action, you may remain a class member without any further obligations, but may miss out on possible recovery.
